Brii Bio Unveils Promising Phase 2 ENSURE Study Findings on BRII-179 for HBV Control

Brii Bio's Breakthrough in Hepatitis B Treatment

Brii Biosciences Limited, a pioneering biotechnology firm, recently shared exciting findings from its Phase 2 ENSURE study during the EASL Congress 2026 in Barcelona. This study, focusing on a potential treatment for hepatitis B virus (HBV), has generated significant interest among medical professionals and health advocates alike.

Study Overview

The ENSURE study (NCT05970289) demonstrates the impact of combining elebsiran, an investigational small interfering ribonucleic acid (siRNA), with pegylated interferon alfa (PEG-IFNα) on chronic HBV infections. Conducted across multiple centers in the Asia-Pacific region, this open-label Phase 2 study aimed to measure the rate of functional cures in participants, specifically those with a baseline hepatitis B surface antigen (HBsAg) of 100-3,000 IU/mL.

Key Findings

Enhanced Functional Cure Rates

The final results were quite telling. The introduction of elebsiran led to a significantly higher functional cure rate compared to those receiving PEG-IFNα alone. Among the participants who had been previously treated with BRII-179, the efficacy was even more pronounced. In Cohort 4, which monitored participants previously administered BRII-179 and elebsiran, an impressive 25.8% achieved a functional cure.
Interestingly, 36.8% of those who responded positively to BRII-179 treatments before the study fully recovered. This underscores the potential of BRII-179 in priming the immune system for enhanced responsiveness to curative therapies.

Mechanism of Action

One of the notable revelations from a translational study accompanying the ENSURE research was the role of BRII-179-induced CD4+ T cells. These T cells showed promising results by attacking HBV epitopes mismatched from circulating virus strains. Their persistence over two years and association with the maturation of hepatitis B-specific B cells provide a deeper understanding of the vaccine's mechanism.

Future Directions

Brii Bio is committed to further exploring BRII-179's potential in treating chronic HBV infections. They are piloting two additional Phase 2b trials—the ENRICH study, which aims to prime immune responses, and the ENHANCE study, focused on optimizing combination regimens involving BRII-179, elebsiran, and PEG-IFNα. Preliminary results are expected in 2026, which may significantly influence future treatment protocols for HBV.

Insights from the Chief Medical Officer

Dr. David Margolis, Brii Bio's Chief Medical Officer, expressed optimism regarding the ENSURE study's findings. He stated, “We believe these final results highlight the potential of BRII-179 and elebsiran in improving functional cure outcomes.” This sentiment is echoed by the broader medical community as they look to Brii Bio's advancements as hope for those battling chronic hepatitis B.

Conclusion

Hepatitis B remains a global health concern, affecting around 254 million individuals and leading to severe health complications, particularly in high-prevalence regions like China. The insights gleaned from the ENSURE study not only inspire confidence in BRII-179's potential effects but also signal an expanded interest in innovative approaches to tackling chronic HBV infection. With ongoing research, Brii Biosciences aims to shed light on complex interactions within the immune system and enhance therapeutic strategies for chronic HBV, ultimately aiming for a functional cure for affected populations.

For more detailed information about Brii Bio's initiatives and ongoing research, please visit Brii Bio's official site.